(Q34042407)

30 July 2017

Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma (English)

1 reference

30 July 2017

1 reference

Catherine Thieblemont

7

object named as

Catherine Thieblemont

1 reference

30 July 2017

Sophie Bernard

1

1 reference

30 July 2017

Damien Danglade

2

1 reference

30 July 2017

Laura Gardano

3

1 reference

30 July 2017

Christelle Laguillier

4

1 reference

30 July 2017

Gregory Lazarian

5

1 reference

30 July 2017

Claudine Roger

6

1 reference

30 July 2017

Jacek Marzec

8

1 reference

30 July 2017

John Gribben

9

1 reference

30 July 2017

Florence Cymbalista

10

1 reference

30 July 2017

Nadine Varin-Blank

11

1 reference

30 July 2017

Dominique Ledoux

12

1 reference

30 July 2017

Fanny Baran-Marszak

13

1 reference

30 July 2017

language of work or name

English

0 references

publication date

3 December 2014

1 reference

International Journal of Cancer

30 July 2017

14

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

30 July 2017

136

1 reference

30 July 2017

12

1 reference

30 July 2017

2761-2774

1 reference

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

30 July 2017

1 reference

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

21 January 2018

1 reference

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

Src-family kinases in B-cell development and signaling

21 January 2018

1 reference

The tipping points in the initiation of B cell signalling: how small changes make big differences.

21 January 2018

1 reference

Tyrosine kinases and their substrates in B lymphocytes

21 January 2018

1 reference

Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

21 January 2018

1 reference

Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma

21 January 2018

1 reference

Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.

21 January 2018

1 reference

SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway

21 January 2018

1 reference

Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting

21 January 2018

1 reference

Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways

21 January 2018

1 reference

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

21 January 2018

1 reference

Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.

21 January 2018

1 reference

The B-cell receptor signaling pathway as a therapeutic target in CLL.

21 January 2018

1 reference

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

21 January 2018

1 reference

The B cell antigen receptor controls integrin activity through Btk and PLCgamma2.

21 January 2018

1 reference

Lymphoma microenvironment: culprit or innocent?

21 January 2018

1 reference

Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach

21 January 2018

1 reference

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

21 January 2018

1 reference

The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies

21 January 2018

1 reference

Targeting pathological B cell receptor signalling in lymphoid malignancies

21 January 2018

1 reference

Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma

21 January 2018

1 reference

Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway.

21 January 2018

1 reference

Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells

21 January 2018

1 reference

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

21 January 2018

1 reference

The SYK tyrosine kinase: a crucial player in diverse biological functions

21 January 2018

1 reference

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

21 January 2018

1 reference

Expression of ZAP70 in chronic lymphocytic leukaemia activates NF-κB signalling.

21 January 2018

1 reference

Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.

21 January 2018

1 reference

Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index

21 January 2018

1 reference

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

21 January 2018

1 reference

VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway.

21 January 2018

1 reference

VEGF producing bone marrow stromal cells (BMSC) enhance vascularization and resorption of a natural coral bone substitute.

21 January 2018

1 reference

Human bone marrow fibroblasts--an overview of their characterization, proliferation and inflammatory mediator production

21 January 2018

1 reference

Ellagic acid inhibits IL-1beta-induced cell adhesion molecule expression in human umbilical vein endothelial cells

21 January 2018

1 reference

STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress

21 January 2018

1 reference

Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin

21 January 2018

1 reference

Bruton's Tyrosine Kinase and Phospholipase Cγ2 Mediate Chemokine-Controlled B Cell Migration and Homing

21 January 2018

1 reference

Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.29326

1 reference

release_6acuqp2tojcsliph3iadqihqg4

30 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6acuqp2tojcsliph3iadqihqg4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference